Federated Hermes Inc. Purchases 206,125 Shares of Inogen, Inc. (NASDAQ:INGN)

Federated Hermes Inc. grew its position in Inogen, Inc. (NASDAQ:INGN) by 347.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 265,485 shares of the medical technology company’s stock after acquiring an additional 206,125 shares during the period. Federated Hermes Inc.’s holdings in Inogen were worth $1,458,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Meros Investment Management LP lifted its holdings in Inogen by 14.9% during the third quarter. Meros Investment Management LP now owns 589,604 shares of the medical technology company’s stock worth $3,078,000 after acquiring an additional 76,294 shares in the last quarter. Kent Lake Capital LLC bought a new stake in shares of Inogen in the third quarter worth about $2,418,000. Acadian Asset Management LLC raised its position in shares of Inogen by 195.6% during the third quarter. Acadian Asset Management LLC now owns 389,792 shares of the medical technology company’s stock worth $2,033,000 after purchasing an additional 257,940 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Inogen by 26.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 285,176 shares of the medical technology company’s stock valued at $1,566,000 after purchasing an additional 59,446 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. grew its position in shares of Inogen by 238.7% in the 3rd quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the medical technology company’s stock valued at $274,000 after purchasing an additional 37,000 shares during the period. Institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

NASDAQ:INGN opened at $7.02 on Tuesday. The stock has a 50-day simple moving average of $7.34 and a 200 day simple moving average of $6.40. Inogen, Inc. has a 52-week low of $4.13 and a 52-week high of $14.10. The company has a market cap of $165.32 million, a PE ratio of -1.59 and a beta of 1.06.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.49). The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $78.09 million. Inogen had a negative net margin of 32.46% and a negative return on equity of 38.98%. On average, research analysts predict that Inogen, Inc. will post -2.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

INGN has been the topic of several research analyst reports. William Blair upgraded shares of Inogen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 15th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.